(Q33388660)

26 July 2017

title

Prolonged systemic circulation of chimeric oncolytic adenovirus Ad5/3-Cox2L-D24 in patients with metastatic and refractory solid tumors (English)

1 reference

26 July 2017

1 reference

1 reference

V Cerullo

6

0 references

Minna Oksanen

12

object named as

M Oksanen

1 reference

26 July 2017

S Pesonen

1

1 reference

26 July 2017

P Nokisalmi

2

1 reference

26 July 2017

S Escutenaire

3

1 reference

26 July 2017

M Särkioja

4

1 reference

26 July 2017

M Raki

5

1 reference

26 July 2017

L Kangasniemi

7

1 reference

26 July 2017

L Laasonen

8

1 reference

26 July 2017

C Ribacka

9

1 reference

26 July 2017

K Guse

10

1 reference

26 July 2017

E Haavisto

11

1 reference

26 July 2017

M Rajecki

13

1 reference

26 July 2017

A Helminen

14

1 reference

26 July 2017

A Ristimäki

15

1 reference

26 July 2017

A Karioja-Kallio

16

1 reference

26 July 2017

E Karli

17

1 reference

26 July 2017

T Kantola

18

1 reference

26 July 2017

G Bauerschmitz

19

1 reference

26 July 2017

A Kanerva

20

1 reference

26 July 2017

T Joensuu

21

1 reference

26 July 2017

A Hemminki

22

1 reference

26 July 2017

publication date

18 March 2010

1 reference

26 July 2017

1 reference

26 July 2017

volume

17

1 reference

26 July 2017

issue

7

1 reference

26 July 2017

page(s)

892-904

1 reference

Cancer selective adenoviruses

26 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FGT.2010.17

7 January 2021

Oncolytic viral therapies

1 reference

https://api.crossref.org/works/10.1038%2FGT.2010.17

7 January 2021

Oncolytic viruses in cancer therapy

1 reference

https://api.crossref.org/works/10.1038%2FGT.2010.17

7 January 2021

Oncolytic viruses from the perspective of the immune system

1 reference

https://api.crossref.org/works/10.1038%2FGT.2010.17

7 January 2021

Effect of adenovirus-mediated heat shock protein expression and oncolysis in combination with low-dose cyclophosphamide treatment on antitumor immune responses

1 reference

https://api.crossref.org/works/10.1038%2FGT.2010.17

7 January 2021

Immune-mediated antitumor activity of reovirus is required for therapy and is independent of direct viral oncolysis and replication

1 reference

https://api.crossref.org/works/10.1038%2FGT.2010.17

7 January 2021

Current developments in adenovirus-based cancer gene therapy

1 reference

https://api.crossref.org/works/10.1038%2FGT.2010.17

7 January 2021

A phase I trial of intravenous CG7870, a replication-selective, prostate-specific antigen-targeted oncolytic adenovirus, for the treatment of hormone-refractory, metastatic prostate cancer.

1 reference

https://api.crossref.org/works/10.1038%2FGT.2010.17

7 January 2021

Clinical trials with oncolytic adenovirus in China

1 reference

https://api.crossref.org/works/10.1038%2FGT.2010.17

7 January 2021

Triple-targeted oncolytic adenoviruses featuring the cox2 promoter, E1A transcomplementation, and serotype chimerism for enhanced selectivity for ovarian cancer cells

1 reference

https://api.crossref.org/works/10.1038%2FGT.2010.17

7 January 2021

Replicative adenoviruses for cancer therapy

1 reference

https://api.crossref.org/works/10.1038%2FGT.2010.17

7 January 2021

Tissue-specific promoters active in CD44+CD24-/low breast cancer cells

1 reference

https://api.crossref.org/works/10.1038%2FGT.2010.17

7 January 2021

https://api.crossref.org/works/10.1038%2FGT.2010.17

1 reference

7 January 2021

A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo.

1 reference

https://api.crossref.org/works/10.1038%2FGT.2010.17

7 January 2021

An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy

1 reference

https://api.crossref.org/works/10.1038%2FGT.2010.17

7 January 2021

Management of malignant bowel obstruction in advanced cancer: a brief review

1 reference

https://api.crossref.org/works/10.1038%2FGT.2010.17

7 January 2021

Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria.

1 reference

https://api.crossref.org/works/10.1038%2FGT.2010.17

7 January 2021

Studies on the use of viruses in the treatment of carcinoma of the cervix

1 reference

https://api.crossref.org/works/10.1038%2FGT.2010.17

7 January 2021

Prostaglandins and cancer

1 reference

https://api.crossref.org/works/10.1038%2FGT.2010.17

7 January 2021

The impact of adenovirus infection on the immunocompromised host

1 reference

https://api.crossref.org/works/10.1038%2FGT.2010.17

7 January 2021

Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer

1 reference

https://api.crossref.org/works/10.1038%2FGT.2010.17

7 January 2021

Serum concentrations of cytokines and lung cancer survival in African Americans and Caucasians

1 reference

https://api.crossref.org/works/10.1038%2FGT.2010.17

7 January 2021

The value of tumor marker and cytokine analysis for the assessment of regional lymph node status in cervical cancer patients

1 reference

https://api.crossref.org/works/10.1038%2FGT.2010.17

7 January 2021

Toll-like receptor 9 triggers an innate immune response to helper-dependent adenoviral vectors.

1 reference

https://api.crossref.org/works/10.1038%2FGT.2010.17

7 January 2021

Efficient, long-term hepatic gene transfer using clinically relevant HDAd doses by balloon occlusion catheter delivery in nonhuman primates

1 reference

https://api.crossref.org/works/10.1038%2FGT.2010.17

7 January 2021

Increased hepatic transduction with reduced systemic dissemination and proinflammatory cytokines following hydrodynamic injection of helper-dependent adenoviral vectors.

1 reference

https://api.crossref.org/works/10.1038%2FGT.2010.17

7 January 2021

Acute toxicity after high-dose systemic injection of helper-dependent adenoviral vectors into nonhuman primates.

1 reference

https://api.crossref.org/works/10.1038%2FGT.2010.17

7 January 2021

A phase I trial of intravenous infusion of ONYX-015 and enbrel in solid tumor patients

1 reference

https://api.crossref.org/works/10.1038%2FGT.2010.17

7 January 2021

Phase I Trial of sequential administration of recombinant DNA and adenovirus expressing L523S protein in early stage non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1038%2FGT.2010.17

7 January 2021

Phase I-II trial of ONYX-015 in combination with MAP chemotherapy in patients with advanced sarcomas

1 reference

https://api.crossref.org/works/10.1038%2FGT.2010.17

7 January 2021

Effect of preexisting immunity on oncolytic adenovirus vector INGN 007 antitumor efficacy in immunocompetent and immunosuppressed Syrian hamsters

1 reference

https://api.crossref.org/works/10.1038%2FGT.2010.17

7 January 2021

A mechanistic perspective of monoclonal antibodies in cancer therapy beyond target-related effects

1 reference

https://api.crossref.org/works/10.1038%2FGT.2010.17

7 January 2021

Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial

1 reference

https://api.crossref.org/works/10.1038%2FGT.2010.17

7 January 2021

Oncolytic adenovirus Ad5/3-delta24 and chemotherapy for treatment of orthotopic ovarian cancer

1 reference

https://api.crossref.org/works/10.1038%2FGT.2010.17

7 January 2021

Enhanced therapeutic efficacy for ovarian cancer with a serotype 3 receptor-targeted oncolytic adenovirus

1 reference

https://api.crossref.org/works/10.1038%2FGT.2010.17

7 January 2021

Clinical research results with dl1520 (Onyx-015), a replication-selective adenovirus for the treatment of cancer: what have we learned?

1 reference

https://api.crossref.org/works/10.1038%2FGT.2010.17

7 January 2021

A smart move against cancer for vaccinia virus

1 reference

https://api.crossref.org/works/10.1038%2FGT.2010.17

7 January 2021

In situ adenovirus vaccination engages T effector cells against cancer

1 reference

https://api.crossref.org/works/10.1038%2FGT.2010.17

7 January 2021

Oncolytic adenovirus CG7870 in combination with radiation demonstrates synergistic enhancements of antitumor efficacy without loss of specificity

1 reference

https://api.crossref.org/works/10.1038%2FGT.2010.17

7 January 2021

Preclinical evaluation of synergistic effect of telomerase-specific oncolytic virotherapy and gemcitabine for human lung cancer

1 reference

https://api.crossref.org/works/10.1038%2FGT.2010.17

7 January 2021

Targeted and armed oncolytic poxviruses: a novel multi-mechanistic therapeutic class for cancer

1 reference

https://api.crossref.org/works/10.1038%2FGT.2010.17

7 January 2021

Oncolytic virus therapy using genetically engineered herpes simplex viruses

1 reference

https://api.crossref.org/works/10.1038%2FGT.2010.17

7 January 2021

Armed therapeutic viruses: strategies and challenges to arming oncolytic viruses with therapeutic genes

1 reference

https://api.crossref.org/works/10.1038%2FGT.2010.17

7 January 2021

Immunosuppression enhances oncolytic adenovirus replication and antitumor efficacy in the Syrian hamster model.

1 reference

https://api.crossref.org/works/10.1038%2FGT.2010.17

7 January 2021

Hexadecyloxypropyl-cidofovir, CMX001, prevents adenovirus-induced mortality in a permissive, immunosuppressed animal model

1 reference

https://api.crossref.org/works/10.1038%2FGT.2010.17

7 January 2021

Cyclooxygenase-2 expression correlates with poor prognosis in pancreatic cancer.

1 reference

https://api.crossref.org/works/10.1038%2FGT.2010.17

7 January 2021

Cell cycle genes in ovarian cancer: steps toward earlier diagnosis and novel therapies

1 reference

https://api.crossref.org/works/10.1038%2FGT.2010.17

7 January 2021

Comparison of one-, two-, and three-dimensional measurements of childhood brain tumors

1 reference

https://api.crossref.org/works/10.1038%2FGT.2010.17

7 January 2021

Gene transfer to ovarian cancer versus normal tissues with fiber-modified adenoviruses

1 reference

https://api.crossref.org/works/10.1038%2FGT.2010.17

7 January 2021

Changing the adenovirus fiber for retaining gene delivery efficacy in the presence of neutralizing antibodies

1 reference

https://api.crossref.org/works/10.1038%2FGT.2010.17

7 January 2021

Identifiers

DOI

10.1038/GT.2010.17

1 reference

Dimensions Publication ID

26 July 2017

1021553080

0 references

1 reference